AR and prostate cancer: AKR1C3 conversion of DHEA-S remaining in patients after leuprolide, Abi, and potentially Enz therapy may feed intratumoral steroidogenesis to replenish AR ligands within prostate cancer cells and contribute to ARSI drug resistance.